NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord injury (SCI).Study also showed a positive trend in the secondary endpoint evaluating change in “GRASSP” score, a measure designed specifically to assess hand function in people with cervical injuries.As the first pharmaceutical candidate to show improved mot ...